Molecule Information
General Information of the Molecule (ID: Mol01014)
| Name |
Multidrug resistance protein 1 (ABCB1)
,Sus scrofa
|
||||
|---|---|---|---|---|---|
| Synonyms |
ABCB1; Fragment
Click to Show/Hide
|
||||
| Molecule Type |
Protein
|
||||
| Gene Name |
ABCB1
|
||||
| Sequence |
GQKKELERYNKNLEEAKRIGIKKAITANISIGAAFLLIYASYALAFWYGTTLVLSNEYTI
GQVLTVFFSVLIGAFSVGQASPSIEAFANARGAAYEIFKIIDSKPSIDSYSKNGHKPDNI KGNLEFRNVHFSYPSRNEVKILKGLNLKVESGQTVALVGNSGCGKSTTVQLMQRLYDPTE GVVSIDGQDIRTINVRYLREIIGVVSQEPVLFATTIAENIRYGRENVTMEEIEKAVKEAN AYDFIMKLPNKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAV VQVALDKAREGRTTIVIAHRLSTVRNADVIAGFDDGVIVEKGSHDELMKEKGVYFKLVTM QTKGNEIELENTVGVSKGVVDALDMSPKDLESSLIRRGSTRKSIKGPQGQDRKLSTKEGL DENVPPVSFWRILKLNITEWPYFVVGIFCAIINGGLQPAFSIIFSRIIGVFTKVTDPETK RQDSNIFSLLFLILGIISFITFFLQGFTFGKAGEILTKRLRYMVFRSMLRQDVSWFDDPK NTTGALTTRLANDAAQVKGAIGSRLAVITQNIANLGTGIIISFIYGWQLTLLLLAIVPII AIAGVVEMKMLSGQALKDKKELEGAGKIATEAIENFRTVVSLTREEKFESMYDQSLQVPY SNSLRKAHIFGITFSITQAMMYFSYAACFRFGAYLVQHGHMDFQDVLLVFSAIVFGAMAV GQVSSFAPDYAKAKVSASHVIMIIEKTPQIDSYSTVGLKPNTVEGNLTFNEVMFNYPTRP DIPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQLLERFYDPLAGKVLIDGREIKELNVQW LRAHMGIVSQEPILFDCSIAENIAYGDNSRVVSQEEIVQAAKEANIHPFIETLPDKYNTR VGDKGTQLSGGQKQRIAIARALVRRPRILLLDEATSALDTESEKVVQEALDKAR Click to Show/Hide
|
||||
| Uniprot ID | |||||
| Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
Drug Resistance Data Categorized by Drug
Approved Drug(s)
3 drug(s) in total
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Psychosis | [1] | |||
| Sensitive Disease | Psychosis [ICD-11: 6D8Z.0] | |||
| Sensitive Drug | Chlorpromazine | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | L-MDR1 cells(Sus scrofa (Pig)) | Kidney | Homo sapiens (Human) | CVCL_0391 |
| LLC-Pk1 cells(Sus scrofa (Pig)) | Kidney | Homo sapiens (Human) | CVCL_0391 | |
| Experiment for Drug Resistance |
Flow cytometric assay | |||
| Mechanism Description | The multidrug resistance transporter, P-glycoprotein (P-gp), is involved in efflux transport of several antipsychotics in the blood-brain barrier (BBB). All the antipsychotics showed various degrees of inhibitory effects on P-gp activity at concentrations ranging from 1 to 100 uM. However, risperidone and olanzapine are the most likely agents that may inhibit P-gp activity. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Psychosis | [1] | |||
| Sensitive Disease | Psychosis [ICD-11: 6D8Z.0] | |||
| Sensitive Drug | Clozapine | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | L-MDR1 cells(Sus scrofa (Pig)) | Kidney | Homo sapiens (Human) | CVCL_0391 |
| LLC-Pk1 cells(Sus scrofa (Pig)) | Kidney | Homo sapiens (Human) | CVCL_0391 | |
| Experiment for Drug Resistance |
Flow cytometric assay | |||
| Mechanism Description | The multidrug resistance transporter, P-glycoprotein (P-gp), is involved in efflux transport of several antipsychotics in the blood-brain barrier (BBB). All the antipsychotics showed various degrees of inhibitory effects on P-gp activity at concentrations ranging from 1 to 100 uM. However, risperidone and olanzapine are the most likely agents that may inhibit P-gp activity. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Psychosis | [1] | |||
| Sensitive Disease | Psychosis [ICD-11: 6D8Z.0] | |||
| Sensitive Drug | Haloperidol | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | L-MDR1 cells(Sus scrofa (Pig)) | Kidney | Homo sapiens (Human) | CVCL_0391 |
| LLC-Pk1 cells(Sus scrofa (Pig)) | Kidney | Homo sapiens (Human) | CVCL_0391 | |
| Experiment for Drug Resistance |
Flow cytometric assay | |||
| Mechanism Description | The multidrug resistance transporter, P-glycoprotein (P-gp), is involved in efflux transport of several antipsychotics in the blood-brain barrier (BBB). All the antipsychotics showed various degrees of inhibitory effects on P-gp activity at concentrations ranging from 1 to 100 uM. However, risperidone and olanzapine are the most likely agents that may inhibit P-gp activity. | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
